Medicinal treatment of primary hyperparathyroidism

Primary hyperparathyroidism (PHPT) is a hyperproduction of parathyroid hormone that not provoked by decrease in the blood calcium level, which leads to violation homeostasis. The prevalence PHPT has been increasing over past 10 years due improvements its diagnosis. Currently, it ranks third this indicator after diabetes and thyroid pathology. leading clinical manifestations are demineralization resorption bone tissue, as well nephrolithiasis development renal failure. It was found glomerular filtration rate inversely correlated with level associated greater mineral density. In addition, frequency left ventricular hypertrophy increases against background significant persistent increase calcium. Patients indicated symptoms an unestablished under supervision orthopedists, cardiologists, family doctors. Monitoring fully addressed issue today. This, particular, fact functioning organizational system for diagnosis pathology significantly increased both number identified patients proportion asymptomatic among them. Some people refuse surgery, currently recognized best option treatment PHPT. Other have contraindications surgery severe comorbid These factors relevance principles medicinal pathology, requires serious analysis existing drugs, their therapeutic potential, risk complications order develop recommendations. questions became basis review article. base scientific publications on pharmacological aspects action drugs were analyzed. full-text articles therapy effectiveness, most common choice bisphosphonates, calcimimetic cinacalcet, vitamin D analogues. Their prospects impact main carefully considered. results will allow clinicians choose individual approach particular patient.